---

---

symbols : Nvo   

save search

---

Novo Nordisk A/S - share repurchase programme
Published: 2024-01-30 (Crawled : 15:30) - globenewswire.com
NVO | News | $124.53 0.88% 0.0% 2.6M |

Health Technology

| 14.23% | O: 0.16% H: 0.13% C: -0.16%
repurchase

---

Transthyretin Amyloidosis Market is Predicted to Exhibit Remarkable Growth by 2032, Predicts DelveInsight | Key Players - Attralus, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, AstraZeneca, Alexion Pharmaceuticals, Novo Nordisk
Published: 2024-01-24 (Crawled : 23:00) - prnewswire.com
NVO | News | $124.53 0.88% 0.0% 2.6M |

Health Technology

| 18.36% | O: 0.49% H: 0.0% C: -0.05%
IONS | $40.93 -1.47% -1.49% 1.1M |

Health Technology

| -19.15% | O: 0.38% H: 2.34% C: 1.56%
key growth market

---

Elo Life Systems Announces Oversubscribed $20.5 Million Series A2 Funding Round
Published: 2024-01-24 (Crawled : 14:00) - prnewswire.com
NVO | News | $124.53 0.88% 0.0% 2.6M |

Health Technology

| 18.18% | O: 1.21% H: 0.36% C: -1.35%
life million series funding

---

Novo Nordisk A/S - share repurchase programme
Published: 2024-01-22 (Crawled : 12:00) - globenewswire.com
NVO | News | $124.53 0.88% 0.0% 2.6M |

Health Technology

| 16.43% | O: -0.6% H: 0.27% C: -0.78%
repurchase

---

Beta-thalassemia Market to Witness Upsurge in Growth During the Study Period (2019-2032), Evaluates DelveInsight | Leading Companies - Vertex Pharmaceuticals, CRISPR Therapeutics, Agios Pharmaceuticals, Celgene, Forma Therapeutics
Published: 2024-01-17 (Crawled : 22:00) - prnewswire.com
NVO | News | $124.53 0.88% 0.0% 2.6M |

Health Technology

| 16.73% | O: -0.36% H: 1.32% C: 1.18%
JNJ | News | $144.77 0.22% -0.01% 9.3M |

Health Technology

| -9.67% | O: -0.21% H: 0.0% C: 0.0%
VRTX | $393.1 -0.27% -0.27% 880K |

Health Technology

| -9.37% | O: -0.5% H: 0.76% C: 0.32%
EDIT | $5.615 -4.02% -4.19% 1.9M |

Health Technology

| -30.44% | O: 0.83% H: 0.35% C: -3.66%
AGIO | $29.03 0.8% 0.79% 500K |

Health Technology

| 32.66% | O: 0.41% H: 0.0% C: -2.2%
crispr companies therapeutics growth study market

---

Cleveland Diagnostics Completes $75M Financing to Advance its Early-detection Oncology Testing Platform
Published: 2024-01-17 (Crawled : 14:30) - biospace.com/
NVO | News | $124.53 0.88% 0.0% 2.6M |

Health Technology

| 17.09% | O: -0.03% H: 0.75% C: 0.34%
diagnostics platform

---

Novo Nordisk A/S - share repurchase programme
Published: 2024-01-15 (Crawled : 11:00) - globenewswire.com
NVO | News | $124.53 0.88% 0.0% 2.6M |

Health Technology

| Email alert Add to watchlist
repurchase

---

Focal Segmental Glomerulosclerosis Market to Observe Impressive Growth by 2032, Predicts DelveInsight | Leading Companies - ACELYRIN, Genentech, ChemoCentryx, Travere Therapeutics, Boehringer Ingelheim, Chinook Therapeutics
Published: 2024-01-10 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.116 -2.18% 2.3K |

Health Technology

| -10.95% | O: 1.1% H: 0.0% C: 0.0%
NVO | News | $124.53 0.88% 0.0% 2.6M |

Health Technology

| 14.59% | O: -0.33% H: 0.35% C: -1.5%
LLY | News | $750.77 0.54% -0.04% 3.1M |

Health Technology

| 19.13% | O: 0.67% H: 0.85% C: 0.21%
SNY | News | $46.125 0.71% 0.7% 3.7M |

Health Technology

| -11.29% | O: 0.69% H: 0.0% C: 0.0%
ALDX 4 | $3.98 2.84% 2.76% 640K |

Health Technology

| 15.87% | O: -1.8% H: 0.46% C: -2.44%
companies therapeutics growth market

---

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Published: 2024-01-09 (Crawled : 16:00) - globenewswire.com
NVO | News | $124.53 0.88% 0.0% 2.6M |

Health Technology

| 17.04% | O: -0.25% H: 0.79% C: 0.77%

---

Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs
Published: 2024-01-08 (Crawled : 13:30) - prnewswire.com
AZNCF | $135.305 -4.19% 1.1K |

Health Technology

| -0.26% | O: 2.71% H: 0.36% C: 0.11%
LEXX | $2.33 0.87% 0.86% 460K |

Health Technology

| 73.33% | O: 0.0% H: 8.15% C: 1.48%
PFE A | $25.42 -1.05% -0.04% 44M |

Health Technology

| -13.74% | O: -0.37% H: 1.09% C: 0.75%
NVO | News | $124.53 0.88% 0.0% 2.6M |

Health Technology

| 17.5% | O: 0.19% H: 0.34% C: 0.21%
MRK | $125.37 0.25% 0.1% 6.1M |

Health Technology

| 6.95% | O: 0.32% H: 0.26% C: -0.18%
AZN | $68.53 0.39% 0.39% 3.7M |

Health Technology

| -0.17% | O: 0.28% H: 0.99% C: 0.93%

---

COMBINE 3 phase 3a trial successfully completed with once-weekly IcoSema demonstrating non-inferior reduction in HbA1c versus daily basal-bolus treatment (insulin glargine U100 and insulin aspart) in people with type 2 diabetes
Published: 2024-01-08 (Crawled : 13:00) - globenewswire.com
NVO | News | $124.53 0.88% 0.0% 2.6M |

Health Technology

| 17.5% | O: 0.19% H: 0.34% C: 0.21%
treatment glargine trial diabetes insulin

---

Novo Nordisk A/S - share repurchase programme
Published: 2024-01-08 (Crawled : 11:00) - globenewswire.com
NVO | News | $124.53 0.88% 0.0% 2.6M |

Health Technology

| 17.5% | O: 0.19% H: 0.34% C: 0.21%
repurchase

---

Novo Nordisk enters into research collaborations with Omega Therapeutics and Cellarity on novel treatment approaches for cardiometabolic diseases
Published: 2024-01-04 (Crawled : 11:00) - globenewswire.com
OMGA | $2.565 6.43% 6.04% 390K |

| -6.23% | O: 92.31% H: 20.0% C: 1.24%
NVO | News | $124.53 0.88% 0.0% 2.6M |

Health Technology

| 20.18% | O: 1.44% H: 3.68% C: 2.4%
treatment research therapeutics

---

2023 Novo Holdings Seed Investments Team Annual Review/Business Update
Published: 2024-01-04 (Crawled : 08:00) - prnewswire.com
NVO | News | $124.53 0.88% 0.0% 2.6M |

Health Technology

| 20.18% | O: 1.44% H: 3.68% C: 2.4%
investments update

---

Nalu Medical, Inc. Announces $65 Million Equity Financing to Advance Treatment for Chronic Neuropathic Pain
Published: 2024-01-03 (Crawled : 17:00) - biospace.com/
NVO | News | $124.53 0.88% 0.0% 2.6M |

Health Technology

| 21.96% | O: -0.06% H: 1.75% C: 1.54%
million treatment

---

Biologics Global Market Forecast Report 2024-2034 - Challenges Posed by Patent Expiration for Biologics
Published: 2023-12-22 (Crawled : 17:00) - prnewswire.com
SNYNF | News | $92.116 -2.18% 2.3K |

Health Technology

| -3.25% | O: 3.66% H: 0.0% C: -0.12%
AZNCF | $135.305 -4.19% 1.1K |

Health Technology

| 3.68% | O: 3.33% H: 0.0% C: -2.93%
NVO | News | $124.53 0.88% 0.0% 2.6M |

Health Technology

| 20.34% | O: -0.31% H: 0.39% C: -0.44%
JNJ | News | $144.77 0.22% -0.01% 9.3M |

Health Technology

| -5.7% | O: 1.09% H: 0.0% C: 0.0%
LLY | News | $750.77 0.54% -0.04% 3.1M |

Health Technology

| 31.25% | O: 0.18% H: 0.5% C: -0.46%
BMY | $47.84 -0.87% -0.02% 12M |

Health Technology

| -5.85% | O: -0.78% H: 5.15% C: 2.81%
ABBV | $164.25 1.05% -0.76% 4M |

Health Technology

| 7.64% | O: 0.58% H: 0.0% C: 0.0%
SNY | News | $46.125 0.71% 0.7% 3.7M |

Health Technology

| -5.38% | O: 1.03% H: 0.0% C: 0.0%
REGN | $901.27 0.8% 0.78% 470K |

Health Technology

| 7.04% | O: 0.52% H: 0.58% C: 0.05%
GILD | $66.94 -0.55% -0.55% 5.3M |

Health Technology

| -15.2% | O: 0.34% H: 1.02% C: 0.59%
BIIB | $192.13 -1.55% -1.57% 1.3M |

Health Technology

| -23.13% | O: 0.57% H: 1.36% C: 1.04%
AZN | $68.53 0.39% 0.39% 3.7M |

Health Technology

| 2.96% | O: 1.06% H: 0.18% C: -1.06%
AMGN | $264.07 -0.59% -0.59% 2.2M |

Health Technology

| -4.44% | O: 0.24% H: 2.03% C: 1.49%
patent report global market

---

Novo Nordisk A/S - share repurchase programme
Published: 2023-12-22 (Crawled : 12:00) - globenewswire.com
NVO | News | $124.53 0.88% 0.0% 2.6M |

Health Technology

| 20.34% | O: -0.31% H: 0.39% C: -0.44%
repurchase

---

Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi
Published: 2023-12-19 (Crawled : 08:00) - biospace.com/
NVO | News | $124.53 0.88% 0.0% 2.6M |

Health Technology

| 25.81% | O: 0.91% H: 0.72% C: 0.11%
SNY | News | $46.125 0.71% 0.7% 3.7M |

Health Technology

| -4.83% | O: 0.45% H: 0.0% C: 0.0%
IPHA | $2.35 -9.27% -10.21% 16K |

Health Technology

| -1.63% | O: 13.88% H: 0.0% C: -3.58%
pharma natural cell sanofi

---

Novo Nordisk A/S - share repurchase programme
Published: 2023-12-18 (Crawled : 13:30) - globenewswire.com
NVO | News | $124.53 0.88% 0.0% 2.6M |

Health Technology

| 28.25% | O: 2.49% H: 0.28% C: -0.54%
repurchase

---

Incretin-based Drugs Market to Reach $73.9 billion, globally, by 2032 at 7.9% CAGR: Allied Market Research
Published: 2023-12-15 (Crawled : 15:30) - prnewswire.com
AZNCF | $135.305 -4.19% 1.1K |

Health Technology

| 2.12% | O: -3.0% H: 2.15% C: 2.15%
NVSEF | News | $93.6375 6.88% 82K |

Health Technology

| -4.45% | O: 0.0% H: 0.0% C: 0.0%
NVO | News | $124.53 0.88% 0.0% 2.6M |

Health Technology

| 27.07% | O: -0.48% H: 0.0% C: -0.44%
NVS | News | $93.08 -0.13% 0.86% 1.2M |

Health Technology

| -5.86% | O: -1.31% H: 0.56% C: -0.17%
LLY | News | $750.77 0.54% -0.04% 3.1M |

Health Technology

| 26.46% | O: -4.44% H: 0.0% C: 0.0%
SNY | News | $46.125 0.71% 0.7% 3.7M |

Health Technology

| -4.53% | O: -0.93% H: 0.0% C: 0.0%
AZN | $68.53 0.39% 0.39% 3.7M |

Health Technology

| 2.89% | O: -2.23% H: 0.28% C: -0.11%
reach research market

---

Gainers vs Losers

56%

44%

Top 10 Gainers

INVO | $1.76 131.58% 56.82% 230M |

Health Technology

SINT | $0.0365 59.39% 37.26% 470M |

Health Technology

WISA 4 | $9.19 50.66% 33.7% 65M |

Electronic Technology

EDBL | News | $6.73 47.91% 32.39% 13M |

GCTK | $0.715 36.27% 26.62% 640K |

Manufacturing

TCON | $2.33 36.26% 26.61% 2M |

Health Technology

TIRX | $0.48 6.43% 24.58% 4.8M |

KZIA | $0.38 30.58% 23.42% 300K |

Health Technology

VNDA | News | $5.23 29.14% 22.56% 24M |

Health Technology

ATNF | $1.91 29.05% 22.51% 310K |

---

Your saved searches

---